BiotechTube
Home/AmMax Bio/Larry Hsu, PhD
LH

Larry Hsu, PhD

Chief Executive Officer

AmMax Bio

Therapeutic Areas

Oncology

AmMax Bio Pipeline

DrugIndicationPhase
AMB-066Colorectal cancer with Minimal residual disease (CRC MRD)Phase 2
AMB-104AML and solid tumorsDiscovery
AMB-051Tenosynovial giant cell tumor (TGCT)Discovery

Leadership Team at AmMax Bio

LZ
Laura Zhu, PhD, MBA
Chief Business Officer
DN
Dorothy Nguyen, MD
VP, Clinical Development
KJ
Kirk Johnson, PhD
Chief Scientific Officer
LA
Laman Alani, PhD
SVP of Product Development
AS
Andrew Sauter
Chief Financial Officer
View full AmMax Bio profile